Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06529978 · ClinicalTrials.gov registry record · NA
Endocardial Mapping With the CoreMap EP Mapping System
A NA study of Persistent Atrial Fibrillation, sponsored by CoreMap.
- Recruiting
- Registry status
- NA
- Development phase
- 245
- Enrollment target
- 3
- Study locations
NCT06529978 is a NA study of Persistent Atrial Fibrillation that is actively recruiting participants, run by CoreMap. The registered enrollment target is 245 participants, below the 1,244-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06529978, a NA study of Persistent Atrial Fibrillation, is actively recruiting participants, sponsored by CoreMap.
- RECRUITING
- Registry status
- NA
- Development phase
- 245 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a global, multi-site, prospective, feasibility study.
Conditions Studied
Interventions
- DEVICE CoreMap EP Mapping System Mapping
- DEVICE CoreMap EP Mapping System Map-Guided Ablation
Study Locations (3)
Florida
- NCH Downtown Baker Hospital - Naples
Vermont
- University of Vermont Medical Center - Burlington
Other
- Na Homolce Hospital - Praha Klanovice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06529978
The ClinicalTrials.gov registry entry for NCT06529978 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,244-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (80% lower). The listed sponsor is CoreMap, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Persistent Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which CoreMap EP Mapping System Mapping is the first listed.
NCT06529978 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Vermont, Other.
Frequently Asked Questions
What is clinical trial NCT06529978 about?
NCT06529978 is a clinical study titled "Endocardial Mapping With the CoreMap EP Mapping System". This is a global, multi-site, prospective, feasibility study.
What is the current status of trial NCT06529978?
This trial is currently recruiting. It is a NA study. The enrollment target is 245 participants. The study started on 2024-07-25. Estimated completion is 2026-12-31.
What conditions does trial NCT06529978 study?
This clinical trial studies the following conditions: Persistent Atrial Fibrillation.
What interventions are being tested in trial NCT06529978?
The interventions under investigation include: CoreMap EP Mapping System Mapping (DEVICE), CoreMap EP Mapping System Map-Guided Ablation (DEVICE).
Who is sponsoring clinical trial NCT06529978?
This trial is sponsored by CoreMap, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06529978 being conducted?
This trial has 3 study locations across Florida, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Persistent Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
ARIADNE Clinical Trial
RECRUITING · NA
-
Medtronic Terminate AF Study
RECRUITING · NA
-
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
RECRUITING · NA
-
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
ACTIVE NOT RECRUITING · NA
-
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.